Identification and Prognostic Value of Key Genes in Hepatocellular Carcinoma

NCT05759858 | Unknown

• 1 other identifier: 2022-0856
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

To explore the key genes of human and mouse hepatocellular carcinoma, identify the key genes and prognostic markers, and develop small molecule drugs targeting the key genes to treat hepatocellular carcinoma.

Conditions

Hepatocellular Carcinoma

Keywords

Hepatocellular carcinoma; Genomes; Prognosis; Gene targeted therapy

Outcome Measures

Primary Outcomes (3)

• Key gene differences in hepatocellular carcinoma

  Key gene differences in hepatocellular carcinoma explored by RNA-seq.

  Through study completion, an average of 1 year.

• Overall survival

  The time from the beginning of treatment to death (for any reason).

  Through study completion, up to 5 years.

• Disease-free survival

  The time from the beginning of treatment to death (for any reason).

  Through study completion, up to 5 years.

Secondary Outcomes (1)

• The incidence and mortality of postoperative hemorrhage, bile leakage and other complications.

  Through study completion, up to 5 years.

Study Arms (1)

Patients with hepatocellular carcinoma confirmed by pathology.

Patients with hepatocellular carcinoma confirmed by pathology.

Other: None of intervention

Interventions

None of intervention OTHER

None of the interventions was applied.

Patients with hepatocellular carcinoma confirmed by pathology.

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients suffered hepatocellular carcinoma which was confirmed by pathology. Only surgical treatment is applied to patients.

You may qualify if:

• Hepatocellular carcinoma confirmed by pathology;
• The patient has no combined organic diseases of heart, lung, and kidney, etc;
• No history of chemotherapy, radiotherapy, upper abdominal surgery, or combined with other tumors;
• The patient has successfully completed the operation and has complete clinical information and pathological data.

You may not qualify if:

• Patients who have previous history of other tumors or have undergone upper abdominal surgery;
• Patients with multiple lesions and distant metastasis;
• Patients who are complicated with organic diseases of important organs such as heart, lung and kidney and cannot tolerate surgery；
• Patients who are more than 75 years old or less than 18 years old.

Sponsors & Collaborators

• Second Affiliated Hospital, School of Medicine, Zhejiang University: lead

Study Sites (1)

2nd Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Samples were restored at -80℃ for 5 years.

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Study Officials

• Sheng Yan, Doctor

  2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

  STUDY CHAIR

• Yang Tian, Doctor

  2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

  STUDY DIRECTOR

• Yuancong Jiang, Doctor

  2nd Affiliated Hospital, School of Medicine, Zhejiang University, China

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Sheng Yan, Doctor

CONTACT

13957161680; shengyan@zju.edu.cn

Yang Tian, Doctor

CONTACT

15088673780

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 26, 2023
• First Posted: March 8, 2023
• Study Start: December 14, 2022
• Primary Completion: December 1, 2025
• Study Completion: December 1, 2025
• Last Updated: March 8, 2023

Record last verified: 2022-12

Locations

CN (1)